Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...

Novo Nordisk and Eli Lilly still have first-mover advantage, but Roche, Pfizer and others all have similar products in the ...

Current health news includes Dexcom's revenue surpassing estimates, Lilly's obesity drug launch in Denmark, and CDC's ...

Saxenda continues to develop a dominant position in obesity pharmacotherapy however, and Novo Nordisk said the drug currently has a market share of 63% worldwide. The company’s GLP-1 agonists ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

We view Novo Nordisk and Eli Lilly as overvalued, with the market likely projecting too much market penetration for obesity drugs or expecting obesity drug pricing to remain stable. In the chart ...

Novo Nordisk (NYSE:NVO), a global healthcare company specializing in diabetes care and other chronic conditions, is positioning itself as a leader in the rapidly evolving obesity treatment landscape.

Lawmakers on Tuesday questioned the maker of popular weight loss drugs Ozempic and Wegovy ... For Wegovy, the committee found that Novo Nordisk charges Americans with obesity $1,349 per month ...

A drug approved to treat obesity ... 10 and older and as Saxenda to treat obesity in adults and children ages 12 to 17. The new study, paid for by Novo Nordisk, included 82 children with a mean ...

Oral Amycretin: This novel oral medication has ... treatment market? The obesity treatment market is becoming increasingly crowded, with multiple pharmaceutical companies investing heavily in research ...